comparemela.com
Home
Live Updates
Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023 : comparemela.com
Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023
/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced the presentations of new biomarker and...
Related Keywords
Stockholm ,
Sweden ,
Japan ,
Tokyo ,
Richard Phillipson ,
International Symposium On Ig ,
International Symposium On Iga Nephropathy Iiga ,
,
Primary Iga ,
International Symposium ,
Iga Nephropathy ,
Chief Medical Officer ,
Full Prescribing ,
Primary Immunoglobulin ,
Investor Relations ,
Calliditas Therapeutics ,
comparemela.com © 2020. All Rights Reserved.